Polo Biology Global Group Corporation
TSX VENTURE : PGG

Polo Biology Global Group Corporation

February 26, 2009 08:00 ET

Polo Biology Global Group Corporation Appoints New CFO and Auditors

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 26, 2009) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Polo Biology Global Group Corporation ("Polo" or the "Company") (TSX VENTURE:PGG), is pleased to announce the appointment of a new officer and auditors.

The Company has appointed Ian Fodie as Chief Financial Officer. Mr. Fodie has had an extensive career, including most recently serving as President and CEO of Oriental Minerals (TSX.V), as the CFO for Longview Capital Partners Inc. (TSX), and former CFO and VP of Operations at Mainframe Entertainment Inc. (TSX). Mr. Fodie studied at the University of Otago in New Zealand where he received his Bachelor of Commerce degree. Mr. Fodie continued on to obtain his Chartered Accountant (New Zealand) designation.

"I am pleased and excited to join Polo and look forward to working with management and the Board," said Mr. Fodie. "The Company is in an attractive and high growth sector with great opportunities lying ahead."

In connection with the Company's recently completed Qualifying Transaction, the Company's Board of Directors has appointed Manning Elliott LLP as the Company's new independent auditors, replacing the firm of Smythe Ratcliffe LLP, which agreed to resign on the completion of the Qualifying Transaction at the request of the Company. There were no reportable events with respect to the change of auditor.

"On behalf of the management team and the Board of Directors, I would like to welcome Ian in joining the Polo team, and I am looking forward to working closely with Ian to maintain and further build a solid foundation to support Polo's growth initiatives," said Paul Wu, President and Chief Executive Officer of Polo Biology Global Group. "I would like to also thank Smythe Ratcliffe LLP for its dedicated service over the past year and a half."

About Polo Biology Global Group Corporation

The Company, through its operating subsidiaries in China, develops, manufactures and distributes health supplements, personal and homecare products across China under the Polo brand. The Company currently distributes its products through Polo Biology, which manages a network of retail outlets operated by its franchisees.

Cautionary Note Regarding Forward-Looking Information

Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with marketing and sale of securities; the need for additional financing; the reliance on key personnel; the potential for conflicts of interest among certain officers, or directors with certain other projects; the volatility of our common share price and volume, and the growth prospects of the Company and the industry within which it operates. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and except as required in accordance with applicable securities legislation, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Polo Biology Global Group Corporation
    Paul Wu
    Chief Executive Officer
    (604) 609-6155
    Email: info@pbggc.com
    or
    Polo Biology Global Group Corporation
    Ali Mahdavi
    Corporate Finance & Investor Relations
    (416) 962-3300
    Email: am@spinnakercmi.com